The Filing Desk

MiniMed Group

MMED · Nasdaq · Health Care · Financials, fiscal 2024 to 2026

MMED · Last close · November 13, 2026
$17.99
Value MiniMed Group yourself

MiniMed Group's revenue rose 14.2% to $3.1 billion in fiscal 2026. Its operating margin was −6.1%, down from −5.4% a year earlier. Free cash flow was −$420 million. The diluted share count rose 1.5%.

MiniMed Group, Inc. Latest fiscal year ended April 24, 2026 10-K filed June 29, 2026 · 0001628280-26-045915 Updated
Revenue
$3.1B
14.2%
Operating margin
−6.1%
0.8 pts
Net income
−$333M
 
Free cash flow
−$420M
 
Return on equity
−9.6%
 
Market cap
$5.1B
Nov 13 close
P/E
—
Loss: no P/E

Operating margin is operating income as a share of revenue. Free cash flow is cash from operations minus capital spending. Return on equity is net income as a share of shareholders' equity. Market cap is the last closing share price times the latest diluted share count, so it is approximate. P/E is the last close divided by diluted earnings per share over the last four quarters, or the latest fiscal year where the quarters aren't available; there is none when the company made a loss.

What MiniMed Group does

MiniMed makes devices and software for people with diabetes who need insulin several times a day. Its main product is an automated insulin delivery system: an insulin pump, a glucose sensor that reads blood sugar continuously, and software that adjusts the insulin dose every five minutes. It also sells a system for people who prefer injections, built around a smart insulin pen and a sensor, along with the supplies and apps that go with them.

MiniMed sells mainly through durable medical equipment suppliers in the United States, with a small share through pharmacies, and it sells in many countries abroad. Its customers are the patients, and doctors and nurses who prescribe its products. It says it competes with other makers of pumps and glucose sensors, and with companies that combine a partner's sensor with their own pump.

MiniMed was formerly part of Medtronic, which still holds a controlling stake. Medtronic has said it intends to give or sell the rest to its own shareholders later. The company has about 8,000 employees and runs two manufacturing facilities.

Its biggest risks, as it describes them

  • Competition from other diabetes device makers, and price pressure on its products.
  • Relying on sole suppliers, including one infusion-set supplier that received an FDA warning letter in January 2026.
  • Failing to build higher-volume manufacturing lines for glucose sensors that meet its quality needs.
  • Medtronic controls the company, and its plan to give up its remaining stake may not happen.
  • Costs and difficulties of operating as a standalone public company after separating from Medtronic.
From MiniMed Group's annual report on Form 10-K, filed June 29, 2026, in our words; the 10-K has the full description and every risk factor. Updated with each new annual report.

Income statement

Revenue and net income
US$ billions, fiscal years; net losses in red. Revenue on the left axis, net income on the right; zero is the same line on both.
Revenue (left axis)Net income (right axis)
Gross profit, R&D and operating income
US$ billions, fiscal years. Gross profit is revenue minus the cost of what was sold; research and development is one of the costs paid from it; what remains after all operating costs is operating income. Losses in red.
Gross profitResearch and developmentOperating income
Margins
Percent of revenue
GrossOperatingNetFree cash flow

MiniMed Group lost money in fiscal 2026: a net loss of $333 million.

Diluted earnings per share
US$ per share, fiscal years, restated for any stock splits; loss years in red.

Returns on capital

Return on capital and on equity
Percent. Return on capital is after-tax operating income over the money invested in the business (debt plus equity, minus cash); return on equity is net income over shareholders' equity. Both use the average of opening and closing balances.
Return on capitalReturn on equity

Balance sheet

Cash and debt
US$ billions, at each fiscal year end. Debt includes finance leases.
Cash and short-term investmentsDebt
Assets, liabilities and equity
US$ billions, at each fiscal year end. Assets equal liabilities plus equity; negative equity in red.
Total assetsTotal liabilitiesShareholders' equity
Debt and liquidity ratios
Times. Debt to equity, current assets over current liabilities, and net debt over EBITDA (a full year's).
Debt to equityCurrent ratioNet debt to EBITDA

Five years at a glance

Fiscal year endFY24FY25FY26
Cash and short-term investments5411298
Debt incl. finance leases———
Net debt (negative means net cash)———
Net debt to EBITDA———
Debt to equity———
Interest coverage———
Current ratio—1.3x1.9x
Quick ratio—0.9x1.4x
US$ millions unless stated, at each fiscal year end. Net debt to EBITDA is debt minus cash, divided by operating income before depreciation and amortization: roughly how many years of those earnings the net debt equals. Debt to equity is debt as a multiple of shareholders' equity. Interest coverage is operating income divided by interest expense. The current ratio is current assets over current liabilities; the quick ratio leaves out inventory.

Cash flow

Cash from operations, capital spending and free cash flow
US$ billions, fiscal years. Free cash flow is cash from operations minus capital spending; negative years in red.
Cash from operationsCapital spendingFree cash flow
Stock-based compensation and buybacks
US$ billions, fiscal years. Shares paid to employees (stock-based compensation, a cost that uses no cash) against cash spent buying shares back. Buybacks that only match it leave the share count roughly where it was.
Stock-based compensationShare buybacks
Dividends and buybacks
US$ billions, cash paid in each fiscal year
DividendsShare buybacks
Diluted share count
Weighted-average diluted shares, millions

Projections

Project MiniMed Group's revenue, net income and earnings per share five years ahead in a bull, a base and a bear case with your own figures, and see the share prices your P/E estimates give them, or value it with a discounted cash flow model. Every projected figure is yours: it is not a forecast of ours.

Insider trades

No officer, director or 10% owner of MiniMed Group reported buying or selling its shares on the open market between November 14, 2025 and November 13, 2026.

From Form 4 filings with the SEC. Grants, option exercises and shares withheld for tax aren't counted. Insider trades at all companies

Indicators

Four widely used measures, worked out from the company's filings. The cutoffs are the ones their authors or users go by, not a verdict of ours.

IndicatorFY25FY26
Piotroski F-score——
Rule of 408.0%0.7%
Altman Z''4.144.28
Accruals ratio—−3.1%
Piotroski F-score: how many of nine simple tests of profitability, funding and efficiency the company passed in the year (Piotroski, 2000); 8 or 9 is strong, 0 to 2 weak. Rule of 40: revenue growth plus free cash flow margin; software investors treat 40% or more as the bar. Altman Z'': working capital, retained earnings, operating income and equity weighed against assets and liabilities (Altman, 1995); Altman puts above 2.6 in the safe zone and below 1.1 in the distress zone. Accruals ratio: net income minus cash from operations, over average total assets; lower means profit is backed by cash.

The nine F-score tests

TestFY25FY26
Net income is positive—Fail
Cash from operations is positivePassFail
Return on assets rose——
Cash from operations exceeds net incomePassPass
Debt fell relative to assets——
Current ratio rose—Pass
Share count didn't risePassFail
Gross margin roseFailFail
Revenue rose relative to assets——
F-score——
Companies that report no gross profit are scored on the other eight.

Compare

Put MiniMed Group side by side with any other company we cover: revenue, growth, margins, cash flow and returns, with ten years of charts.

Similar companies

CompanyYearRevenue growthOperating marginFree cash flow marginReturn on capitalNet debt to EBITDAF-scoreCompare
MiniMed GroupFY2614.2%−6.1%−13.5%———
AdaptHealthFY25−0.5%2.8%6.8%2.1%3.5x4Compare
Globus MedicalFY2516.6%16.3%20.0%11.0%−0.7x9Compare
RevvityFY253.7%12.5%17.8%3.3%3.0x5Compare
BrukerFY252.1%2.0%1.3%0.9%5.5x4Compare
Each company's latest fiscal year. Fiscal years end in different months, so the periods don't line up exactly. Free cash flow margin is free cash flow as a share of revenue. Net debt to EBITDA is explained under the balance sheet, and the F-score under Indicators.

3 years of figures

Fiscal yearFY24FY25FY26
Income statement
Revenue2,4692,7153,102
Revenue growth—10.0%14.2%
Gross profit1,4361,5281,680
Research and development437436448
Operating income−69−146−190
Net income−112−213−333
Diluted EPS (US$)−0.44−0.84−1.30
Diluted shares (millions)253253257
Cash flow
Cash from operations41140−197
Capital expenditure148193223
Free cash flow−107−53−420
Dividends paid000
Share buybacks000
Acquisitions000
Stock-based compensation384146
Balance sheet at fiscal year end
Cash and short-term investments5411298
Debt incl. finance leases———
Total assets—4,2014,630
Total liabilities—8711,019
Shareholders' equity3,4483,3303,611
Margins and ratios
Gross margin58.2%56.3%54.2%
Operating margin−2.8%−5.4%−6.1%
Net margin−4.5%−7.8%−10.7%
Free cash flow margin−4.3%−1.9%−13.5%
Rule of 40 (growth + FCF margin)—8.0%0.7%
Return on capital———
Return on equity——−9.6%
Return on assets——−7.5%
Net debt to EBITDA———
US$ millions unless stated. Where a later 10-K restated a year, the latest filed figure is shown. Download all figures (CSV, US$ millions)
Source: MiniMed Group's Form 10-K filings, from SEC EDGAR. For information only, not investment advice. The Filing Desk is not affiliated with MiniMed Group.